254 related articles for article (PubMed ID: 28935545)
1. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
[TBL] [Abstract][Full Text] [Related]
2. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
Riggins RB; Lan JP; Zhu Y; Klimach U; Zwart A; Cavalli LR; Haddad BR; Chen L; Gong T; Xuan J; Ethier SP; Clarke R
Cancer Res; 2008 Nov; 68(21):8908-17. PubMed ID: 18974135
[TBL] [Abstract][Full Text] [Related]
3. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
[TBL] [Abstract][Full Text] [Related]
4. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
[TBL] [Abstract][Full Text] [Related]
5. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
[TBL] [Abstract][Full Text] [Related]
6. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
7. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
8. A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
Blawski R; Toska E
Cancer Res; 2022 Oct; 82(20):3668-3670. PubMed ID: 36245246
[TBL] [Abstract][Full Text] [Related]
9. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
[TBL] [Abstract][Full Text] [Related]
10. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
[TBL] [Abstract][Full Text] [Related]
11. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
12. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
Heckler MM; Thakor H; Schafer CC; Riggins RB
FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
[TBL] [Abstract][Full Text] [Related]
13. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
14. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma.
Tasdemir N; Ding K; Savariau L; Levine KM; Du T; Elangovan A; Bossart EA; Lee AV; Davidson NE; Oesterreich S
Sci Rep; 2020 Jul; 10(1):11487. PubMed ID: 32661241
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
[TBL] [Abstract][Full Text] [Related]
16. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
[TBL] [Abstract][Full Text] [Related]
17. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
20. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
Chen F; Ding K; Priedigkeit N; Elangovan A; Levine KM; Carleton N; Savariau L; Atkinson JM; Oesterreich S; Lee AV
Cancer Res; 2021 Jan; 81(2):268-281. PubMed ID: 33148662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]